Erasca partners with Bristol Myers Squibb on pancreatic cancer drug trial
ERAS•Erasca entered a nonexclusive clinical trial collaboration and supply agreement with Bristol Myers Squibb to test ERAS-0015 with navlimetostat in a Phase 1/2 trial for patients with MTAP-deleted pancreatic ductal adenocarcinoma.




